What is speculation / overstatement / weakly supported
• “RWE from UK Specials programs including poly-ICLC since Jan 2016 is the insurance for approval.”
• Why this is weak: Using trial/compassionate-use data or “Specials” experience to guarantee approval is speculative. Regulators base decisions on controlled clinical data, statistical analyses, manufacturing, safety/CMC, and benefit-risk assessments — real-world evidence can help but rarely substitutes for robust, peer-reviewed phase-3 findings and regulatory dossier completeness. There’s no public MHRA statement saying RWE alone will carry DCVax-L to approval. GOV.UKBrain Tumour Research
• “All those DC vaccine trials with amazing efficacy are related to NWBO’s core technology”
• Why this is unlikely: “Dendritic-cell vaccines” is a broad class; many groups use different manufacturing methods, antigens, adjuvants and protocols. You can’t assume efficacy in unrelated DC platforms automatically validates NWBO’s product. That’s a logical leap. (The existence of positive DC vaccine trials doesn’t prove any one company’s product will get approval.) BioMed Central
• Spin-offs merging (Mill Creek / Immuorestoration ? NWBO) and a guaranteed “LP surprise” / FDA pilot voucher leading to approval
• Those are corporate-structuring and regulatory-timing guesses. They may be investor speculation more than documented facts. No authoritative regulatory or company filing confirms a guaranteed merger or an approval timeline based on a “pilot voucher” in the way the poster asserts. Northwest BiotherapeuticsAInvest
• “Add Keytruda ? blockbuster results” (claim applied as certainty)
• Combining a DC vaccine + PD-1 blockade can be synergistic in theory and in some small trials, but it is not guaranteed to be “blockbuster.” Immuno-oncology combos can fail for safety, lack of efficacy, or reproducibility; small phase-I signals don’t ensure large phase-3 success. Clinical evidence and randomized trials are needed.
Market Data 
Markets 
AI
